NONSTEROIDAL ANTI-INFLAMMATORY DRUG-SPARING EFFECT OF SECUKINUMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 4-YEAR RESULTS FROM THE MEASURE 2, 3 AND 4 PHASE 3 TRIALS

被引：0
|
作者：
Dougados, M. [1 ]
Kiltz, U. [2 ,3 ]
Kivitz, A. [4 ]
Pavelka, K. [5 ]
Rohrer, S. [5 ]
Mccreddin, S. [7 ]
Quebe-Fehling, E. [6 ]
Porter, B. [8 ]
Talloczy, Z. [8 ]
机构：
[1] Univ Paris, Dept Rheumatol, Hop Cochin, Paris, France
[2] Rheumazentrum Ruhrgebiet, Herne, Germany
[3] Ruhr Univ, Bochum, Germany
[4] Altoona Ctr Clin Res, Duncansville, PA USA
[5] Inst Rheumatol, Dept Rheumatol, Prague, Czech Republic
[6] Novartis Pharma AG, Basel, Switzerland
[7] Novartis Ireland Ltd, Dublin, Ireland
[8] Novartis Pharmaceut, E Hanover, NJ USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.824
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0374
引用
收藏
页码：415 / 416
页数：2
相关论文
共 50 条
  • [31] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A PHASE 3 TRIAL WITH SUBCUTANEOUS LOADING AND MAINTENANCE DOSING (MEASURE 2)
    Marzo-Ortega, H.
    Legerton, C. W.
    Sieper, J.
    Kivitz, A.
    Blanco, R.
    Cohen, M.
    Zuazo, J.
    Readie, A.
    Porter, B.
    Richards, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 812 - 813
  • [32] ASAS, BASDAI AND ASDAS REMISSION IN SECUKINUMAB TREATED PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A POOLED ANALYSIS OF TWO PHASE 3 STUDIES
    Baraliakos, X.
    Van den Bosch, F.
    Machado, P.
    Gensler, L.
    Bintu, S.
    Porter, B.
    Gaillez, C.
    Deodhar, A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (04) : 743 - 743
  • [33] High Retention Rate and Sustained Responses with Secukinumab 150mg in Patients with Active Ankylosing Spondylitis: 3-Year Results from a Phase 3 Study
    Kivitz, Alan J.
    Marzo-Ortega, Helena
    Legerton, Clarence
    Sieper, Joachim
    Blanco, Ricardo
    Cohen, Martin
    Delicha, Evie Maria
    Rohrer, Susanne
    Richards, Hanno
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [34] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 4-YEAR RESULTS FROM THE PHASE 3 FUTURE 2 STUDY
    McInnes, Iain B.
    Kirkham, Bruce
    Nash, Peter
    Rahman, Proton
    Gottlieb, Alice B.
    Ding, Kevin
    Pricop, Luminita
    RHEUMATOLOGY, 2019, 58
  • [35] Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis
    Atul Deodhar
    Servet Akar
    Jeffrey R. Curtis
    Bassel El-Zorkany
    Marina Magrey
    Cunshan Wang
    Joseph Wu
    Solomon B. Makgoeng
    Ivana Vranic
    Sujatha Menon
    Dona L. Fleishaker
    Annette M. Diehl
    Lara Fallon
    Arne Yndestad
    Robert B. M. Landewé
    Advances in Rheumatology, 64 (1)
  • [36] EFFECT OF SECUKINUMAB, AN INTERLEUKIN-17A INHIBITOR, ON SPINAL RADIOGRAPHIC CHANGES THROUGH 2 YEARS IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS OF THE PHASE 3 STUDY, MEASURE 1
    Braun, J.
    Baraliakos, X.
    Deodhar, A.
    Baeten, D.
    Sieper, J.
    Emery, P.
    Talloczy, Z.
    Martin, R.
    Richards, H. B.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 52 - 52
  • [37] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A PHASE 3 TRIAL WITH SUBCUTANEOUS LOADING AND MAINTENANCE DOSING (MEASURE-2)
    Marzo-Ortega, H.
    Legerton, C. W.
    Sieper, J.
    Kivitz, A.
    Blanco, R.
    Cohen, M.
    Martin, R.
    Readie, A.
    Richards, H.
    Porter, B.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : 783 - 783
  • [38] SUSTAINED IMPROVEMENTS IN SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS AND REASSURING SAFETY WITH SECUKINUMAB 300 MG: 3-YEAR RESULTS FROM A PHASE 3 STUDY
    Cecena, Marco Maradiaga
    Kivitz, Alan J.
    Pavelka, Karel
    Dokoupilova, Eva
    Blanco, Ricardo
    Tahir, Hasan
    Wang, Yi
    Porter, Brian
    Stefanska, Anna
    Rohrer, Susanne
    Richards, Hanno
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 : S4 - S5
  • [39] Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J)
    Kishimoto, Mitsumasa
    Taniguchi, Atsuo
    Fujishige, Ayako
    Kaneko, Shuhei
    Haemmerle, Sibylle
    Porter, Brian O.
    Kobayashi, Shigeto
    MODERN RHEUMATOLOGY, 2020, 30 (01) : 132 - 140
  • [40] Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial
    Baraliakos, X.
    Kivitz, J.
    Deodhar, A. A.
    Braun, J.
    Wei, J. C.
    Delicha, E. M.
    Talloczy, Z.
    Porter, B.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (01) : 50 - 55
12345